The AstraZeneca vaccine has been deemed as safe to use by the European Medicines Agency.
Following a review by the EMA, the body has deemed the jab safe to administer and said that the benefits outweigh the risks associated with the vaccine.
However the Agency has added that they could not definitively rule out a connection between a risk of clotting and the vaccine.
Emer Cooke, head of the EMA said the committee reviewing the cases concluded that the vaccine is not associated with increased risk of clotting but she said they would continue to study possible links between rare blood clot events and the vaccine and said it remained important to keep track of all possible side effects.
The EMA’s safety committee decided to “draw attention to these possible rare conditions” by having details included in its leaflets.
Ireland has suspended the use of the vaccine pending the results of the EMA's investigation however HSE Chief Paul Reid has said that it will resume administering the jab once it got the OK.
However Minister for Transport Eamon Ryan said it could take a couple of days before the rollout of the vaccine begins again.
Meanwhile there have been calls for an "urgent review" of the vaccine priority list to include heart failure patients, as studies show more than half of this group who contract Covid-19 subsequently die.
The data came from the Irish Heart Foundation and the HSE.
Younger people living with severe heart failure are not deemed at very high risk under the national immunisation programme.
